CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
SUBLICENSE REVENUE	$ 0	$ 0	$ 2,000	$ 0
OPERATING EXPENSES:
Sublicense transaction costs	0	0	254	0
General and administrative	126	159	439	374
Research and development	507	386	1,130	765
Total operating expenses	633	545	1,823	1,139
Income (loss) after operating expenses	(633)	(545)	177	(1,139)
Interest and other income (expense), net	(60)	(61)	(182)	(70)
Income (loss) from operations before taxes	(693)	(606)	(5)	(1,209)
Income tax benefit	0	8	3	18
NET INCOME (LOSS)	(693)	(598)	(2)	(1,191)
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ (693)	$ (598)	$ (2)	$ (1,191)
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ (0.01)	$ (0.01)	$ 0	$ (0.03)
Basic and diluted shares outstanding	54,385	52,331	54,385	44,743